"alt_sample_name"	"unique_patient_ID"	"sample_type"	"histological_type"	"primarysite"	"arrayedsite"	"summarygrade"	"summarystage"	"tumorstage"	"substage"	"grade"	"age_at_initial_pathologic_diagnosis"	"pltx"	"tax"	"neo"	"days_to_tumor_recurrence"	"recurrence_status"	"days_to_death"	"vital_status"	"os_binary"	"relapse_binary"	"site_of_tumor_first_recurrence"	"primary_therapy_outcome_success"	"debulking"	"percent_normal_cells"	"percent_stromal_cells"	"percent_tumor_cells"	"batch"	"uncurated_author_metadata"
"GSM432220"	"Serous ovarian cancer 10"	NA	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	NA	"y"	"y"	NA	1650	"norecurrence"	1650	"living"	NA	NA	NA	NA	"optimal"	NA	NA	NA	NA	"title: Serous ovarian cancer 10///geo_accession: GSM432220///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 3///characteristics_ch1.1: Stage: IIIc///characteristics_ch1.2: cytoreductive surgery: optimal///characteristics_ch1.3: progression-free survival (m): 55///characteristics_ch1.4: recurrence (1): 0///characteristics_ch1.5: overall survival (m): 55///characteristics_ch1.6: death (1): 0///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: yoshikou@med.niigata-u.ac.jp///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432220/GSM432220.txt.gz///data_row_count: 41000///relation: "
"GSM432221"	"Serous ovarian cancer 100"	NA	"tumor"	"ser"	"ov"	NA	"high"	"late"	4	NA	3	NA	"y"	"y"	NA	30	"recurrence"	30	"deceased"	NA	NA	NA	NA	"suboptimal"	NA	NA	NA	NA	"title: Serous ovarian cancer 100///geo_accession: GSM432221///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 3///characteristics_ch1.1: Stage: IV///characteristics_ch1.2: cytoreductive surgery: not optimal///characteristics_ch1.3: progression-free survival (m): 1///characteristics_ch1.4: recurrence (1): 1///characteristics_ch1.5: overall survival (m): 1///characteristics_ch1.6: death (1): 1///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: yoshikou@med.niigata-u.ac.jp///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432221/GSM432221.txt.gz///data_row_count: 41000///relation: "
"GSM432222"	"Serous ovarian cancer 104"	NA	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	NA	"y"	"y"	NA	720	"norecurrence"	720	"living"	NA	NA	NA	NA	"suboptimal"	NA	NA	NA	NA	"title: Serous ovarian cancer 104///geo_accession: GSM432222///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 3///characteristics_ch1.1: Stage: IIIc///characteristics_ch1.2: cytoreductive surgery: not optimal///characteristics_ch1.3: progression-free survival (m): 24///characteristics_ch1.4: recurrence (1): 0///characteristics_ch1.5: overall survival (m): 24///characteristics_ch1.6: death (1): 0///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: yoshikou@med.niigata-u.ac.jp///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432222/GSM432222.txt.gz///data_row_count: 41000///relation: "
"GSM432223"	"Serous ovarian cancer 106"	NA	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	NA	"y"	"y"	NA	450	"recurrence"	780	"living"	NA	NA	NA	NA	"suboptimal"	NA	NA	NA	NA	"title: Serous ovarian cancer 106///geo_accession: GSM432223///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 15 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 3///characteristics_ch1.1: Stage: IIIc///characteristics_ch1.2: cytoreductive surgery: not optimal///characteristics_ch1.3: progression-free survival (m): 15///characteristics_ch1.4: recurrence (1): 1///characteristics_ch1.5: overall survival (m): 26///characteristics_ch1.6: death (1): 0///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: yoshikou@med.niigata-u.ac.jp///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432223/GSM432223.txt.gz///data_row_count: 41000///relation: Reanalyzed by: GSM795125"
"GSM432224"	"Serous ovarian cancer 107"	NA	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	NA	"y"	"y"	NA	510	"recurrence"	990	"deceased"	NA	NA	NA	NA	"suboptimal"	NA	NA	NA	NA	"title: Serous ovarian cancer 107///geo_accession: GSM432224///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 3///characteristics_ch1.1: Stage: IIIc///characteristics_ch1.2: cytoreductive surgery: not optimal///characteristics_ch1.3: progression-free survival (m): 17///characteristics_ch1.4: recurrence (1): 1///characteristics_ch1.5: overall survival (m): 33///characteristics_ch1.6: death (1): 1///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: yoshikou@med.niigata-u.ac.jp///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432224/GSM432224.txt.gz///data_row_count: 41000///relation: "
"GSM432225"	"Serous ovarian cancer 108"	NA	"tumor"	"ser"	"ov"	NA	"low"	"late"	3	"b"	1	NA	"y"	"y"	NA	1110	"norecurrence"	1110	"living"	NA	NA	NA	NA	"optimal"	NA	NA	NA	NA	"title: Serous ovarian cancer 108///geo_accession: GSM432225///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 15 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 1///characteristics_ch1.1: Stage: IIIb///characteristics_ch1.2: cytoreductive surgery: optimal///characteristics_ch1.3: progression-free survival (m): 37///characteristics_ch1.4: recurrence (1): 0///characteristics_ch1.5: overall survival (m): 37///characteristics_ch1.6: death (1): 0///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: yoshikou@med.niigata-u.ac.jp///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432225/GSM432225.txt.gz///data_row_count: 41000///relation: Reanalyzed by: GSM795126"
"GSM432226"	"Serous ovarian cancer 109"	NA	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	NA	"y"	"y"	NA	210	"recurrence"	600	"deceased"	NA	NA	NA	NA	"suboptimal"	NA	NA	NA	NA	"title: Serous ovarian cancer 109///geo_accession: GSM432226///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 15 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 3///characteristics_ch1.1: Stage: IIIc///characteristics_ch1.2: cytoreductive surgery: not optimal///characteristics_ch1.3: progression-free survival (m): 7///characteristics_ch1.4: recurrence (1): 1///characteristics_ch1.5: overall survival (m): 20///characteristics_ch1.6: death (1): 1///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: yoshikou@med.niigata-u.ac.jp///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432226/GSM432226.txt.gz///data_row_count: 41000///relation: Reanalyzed by: GSM795127"
"GSM432227"	"Serous ovarian cancer 11"	NA	"tumor"	"ser"	"ov"	NA	"low"	"late"	3	"b"	2	NA	"y"	"y"	NA	1380	"recurrence"	1410	"living"	NA	NA	NA	NA	"optimal"	NA	NA	NA	NA	"title: Serous ovarian cancer 11///geo_accession: GSM432227///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 2///characteristics_ch1.1: Stage: IIIb///characteristics_ch1.2: cytoreductive surgery: optimal///characteristics_ch1.3: progression-free survival (m): 46///characteristics_ch1.4: recurrence (1): 1///characteristics_ch1.5: overall survival (m): 47///characteristics_ch1.6: death (1): 0///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: yoshikou@med.niigata-u.ac.jp///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432227/GSM432227.txt.gz///data_row_count: 41000///relation: "
"GSM432228"	"Serous ovarian cancer 110"	NA	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	NA	"y"	"y"	NA	1800	"norecurrence"	1800	"living"	NA	NA	NA	NA	"suboptimal"	NA	NA	NA	NA	"title: Serous ovarian cancer 110///geo_accession: GSM432228///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 15 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 3///characteristics_ch1.1: Stage: IIIc///characteristics_ch1.2: cytoreductive surgery: not optimal///characteristics_ch1.3: progression-free survival (m): 60///characteristics_ch1.4: recurrence (1): 0///characteristics_ch1.5: overall survival (m): 60///characteristics_ch1.6: death (1): 0///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: yoshikou@med.niigata-u.ac.jp///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432228/GSM432228.txt.gz///data_row_count: 41000///relation: Reanalyzed by: GSM795128"
"GSM432229"	"Serous ovarian cancer 111"	NA	"tumor"	"ser"	"ov"	NA	"low"	"late"	3	"c"	2	NA	"y"	"y"	NA	540	"recurrence"	1710	"deceased"	NA	NA	NA	NA	"suboptimal"	NA	NA	NA	NA	"title: Serous ovarian cancer 111///geo_accession: GSM432229///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 15 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 2///characteristics_ch1.1: Stage: IIIc///characteristics_ch1.2: cytoreductive surgery: not optimal///characteristics_ch1.3: progression-free survival (m): 18///characteristics_ch1.4: recurrence (1): 1///characteristics_ch1.5: overall survival (m): 57///characteristics_ch1.6: death (1): 1///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: yoshikou@med.niigata-u.ac.jp///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432229/GSM432229.txt.gz///data_row_count: 41000///relation: Reanalyzed by: GSM795129"
"GSM432230"	"Serous ovarian cancer 112"	NA	"tumor"	"ser"	"ov"	NA	"low"	"late"	3	"a"	2	NA	"y"	"y"	NA	1440	"norecurrence"	1440	"living"	NA	NA	NA	NA	"optimal"	NA	NA	NA	NA	"title: Serous ovarian cancer 112///geo_accession: GSM432230///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 2///characteristics_ch1.1: Stage: IIIa///characteristics_ch1.2: cytoreductive surgery: optimal///characteristics_ch1.3: progression-free survival (m): 48///characteristics_ch1.4: recurrence (1): 0///characteristics_ch1.5: overall survival (m): 48///characteristics_ch1.6: death (1): 0///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: yoshikou@med.niigata-u.ac.jp///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432230/GSM432230.txt.gz///data_row_count: 41000///relation: "
"GSM432231"	"Serous ovarian cancer 113"	NA	"tumor"	"ser"	"ov"	NA	"low"	"late"	3	"c"	1	NA	"y"	"y"	NA	1290	"recurrence"	2070	"living"	NA	NA	NA	NA	"suboptimal"	NA	NA	NA	NA	"title: Serous ovarian cancer 113///geo_accession: GSM432231///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 1///characteristics_ch1.1: Stage: IIIc///characteristics_ch1.2: cytoreductive surgery: not optimal///characteristics_ch1.3: progression-free survival (m): 43///characteristics_ch1.4: recurrence (1): 1///characteristics_ch1.5: overall survival (m): 69///characteristics_ch1.6: death (1): 0///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: yoshikou@med.niigata-u.ac.jp///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432231/GSM432231.txt.gz///data_row_count: 41000///relation: "
"GSM432232"	"Serous ovarian cancer 114"	NA	"tumor"	"ser"	"ov"	NA	"low"	"late"	3	"c"	1	NA	"y"	"y"	NA	240	"recurrence"	810	"deceased"	NA	NA	NA	NA	"suboptimal"	NA	NA	NA	NA	"title: Serous ovarian cancer 114///geo_accession: GSM432232///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 1///characteristics_ch1.1: Stage: IIIc///characteristics_ch1.2: cytoreductive surgery: not optimal///characteristics_ch1.3: progression-free survival (m): 8///characteristics_ch1.4: recurrence (1): 1///characteristics_ch1.5: overall survival (m): 27///characteristics_ch1.6: death (1): 1///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: yoshikou@med.niigata-u.ac.jp///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432232/GSM432232.txt.gz///data_row_count: 41000///relation: "
"GSM432233"	"Serous ovarian cancer 115"	NA	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"b"	3	NA	"y"	"y"	NA	360	"recurrence"	2070	"deceased"	NA	NA	NA	NA	"suboptimal"	NA	NA	NA	NA	"title: Serous ovarian cancer 115///geo_accession: GSM432233///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 3///characteristics_ch1.1: Stage: IIIb///characteristics_ch1.2: cytoreductive surgery: not optimal///characteristics_ch1.3: progression-free survival (m): 12///characteristics_ch1.4: recurrence (1): 1///characteristics_ch1.5: overall survival (m): 69///characteristics_ch1.6: death (1): 1///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: yoshikou@med.niigata-u.ac.jp///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432233/GSM432233.txt.gz///data_row_count: 41000///relation: "
"GSM432234"	"Serous ovarian cancer 116"	NA	"tumor"	"ser"	"ov"	NA	"low"	"late"	3	"c"	1	NA	"y"	"y"	NA	420	"recurrence"	1530	"deceased"	NA	NA	NA	NA	"suboptimal"	NA	NA	NA	NA	"title: Serous ovarian cancer 116///geo_accession: GSM432234///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 1///characteristics_ch1.1: Stage: IIIc///characteristics_ch1.2: cytoreductive surgery: not optimal///characteristics_ch1.3: progression-free survival (m): 14///characteristics_ch1.4: recurrence (1): 1///characteristics_ch1.5: overall survival (m): 51///characteristics_ch1.6: death (1): 1///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: yoshikou@med.niigata-u.ac.jp///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432234/GSM432234.txt.gz///data_row_count: 41000///relation: "
"GSM432235"	"Serous ovarian cancer 117"	NA	"tumor"	"ser"	"ov"	NA	"low"	"late"	3	"c"	2	NA	"y"	"y"	NA	510	"norecurrence"	510	"living"	NA	NA	NA	NA	"optimal"	NA	NA	NA	NA	"title: Serous ovarian cancer 117///geo_accession: GSM432235///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 2///characteristics_ch1.1: Stage: IIIc///characteristics_ch1.2: cytoreductive surgery: optimal///characteristics_ch1.3: progression-free survival (m): 17///characteristics_ch1.4: recurrence (1): 0///characteristics_ch1.5: overall survival (m): 17///characteristics_ch1.6: death (1): 0///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: yoshikou@med.niigata-u.ac.jp///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432235/GSM432235.txt.gz///data_row_count: 41000///relation: "
"GSM432236"	"Serous ovarian cancer 118"	NA	"tumor"	"ser"	"ov"	NA	"low"	"late"	3	"c"	2	NA	"y"	"y"	NA	240	"recurrence"	510	"living"	NA	NA	NA	NA	"suboptimal"	NA	NA	NA	NA	"title: Serous ovarian cancer 118///geo_accession: GSM432236///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 2///characteristics_ch1.1: Stage: IIIc///characteristics_ch1.2: cytoreductive surgery: not optimal///characteristics_ch1.3: progression-free survival (m): 8///characteristics_ch1.4: recurrence (1): 1///characteristics_ch1.5: overall survival (m): 17///characteristics_ch1.6: death (1): 0///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: yoshikou@med.niigata-u.ac.jp///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432236/GSM432236.txt.gz///data_row_count: 41000///relation: "
"GSM432237"	"Serous ovarian cancer 119"	NA	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	NA	"y"	"y"	NA	510	"norecurrence"	510	"living"	NA	NA	NA	NA	"optimal"	NA	NA	NA	NA	"title: Serous ovarian cancer 119///geo_accession: GSM432237///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 3///characteristics_ch1.1: Stage: IIIc///characteristics_ch1.2: cytoreductive surgery: optimal///characteristics_ch1.3: progression-free survival (m): 17///characteristics_ch1.4: recurrence (1): 0///characteristics_ch1.5: overall survival (m): 17///characteristics_ch1.6: death (1): 0///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: yoshikou@med.niigata-u.ac.jp///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432237/GSM432237.txt.gz///data_row_count: 41000///relation: "
"GSM432238"	"Serous ovarian cancer 12"	NA	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	NA	"y"	"y"	NA	240	"recurrence"	720	"deceased"	NA	NA	NA	NA	"optimal"	NA	NA	NA	NA	"title: Serous ovarian cancer 12///geo_accession: GSM432238///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 3///characteristics_ch1.1: Stage: IIIc///characteristics_ch1.2: cytoreductive surgery: optimal///characteristics_ch1.3: progression-free survival (m): 8///characteristics_ch1.4: recurrence (1): 1///characteristics_ch1.5: overall survival (m): 24///characteristics_ch1.6: death (1): 1///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: yoshikou@med.niigata-u.ac.jp///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432238/GSM432238.txt.gz///data_row_count: 41000///relation: "
"GSM432239"	"Serous ovarian cancer 120"	NA	"tumor"	"ser"	"ov"	NA	"low"	"late"	4	NA	2	NA	"y"	"y"	NA	180	"recurrence"	1560	"deceased"	NA	NA	NA	NA	"suboptimal"	NA	NA	NA	NA	"title: Serous ovarian cancer 120///geo_accession: GSM432239///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 2///characteristics_ch1.1: Stage: IV///characteristics_ch1.2: cytoreductive surgery: not optimal///characteristics_ch1.3: progression-free survival (m): 6///characteristics_ch1.4: recurrence (1): 1///characteristics_ch1.5: overall survival (m): 52///characteristics_ch1.6: death (1): 1///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: yoshikou@med.niigata-u.ac.jp///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432239/GSM432239.txt.gz///data_row_count: 41000///relation: "
"GSM432240"	"Serous ovarian cancer 122"	NA	"tumor"	"ser"	"ov"	NA	"low"	"late"	3	"c"	2	NA	"y"	"y"	NA	240	"recurrence"	750	"deceased"	NA	NA	NA	NA	"suboptimal"	NA	NA	NA	NA	"title: Serous ovarian cancer 122///geo_accession: GSM432240///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 2///characteristics_ch1.1: Stage: IIIc///characteristics_ch1.2: cytoreductive surgery: not optimal///characteristics_ch1.3: progression-free survival (m): 8///characteristics_ch1.4: recurrence (1): 1///characteristics_ch1.5: overall survival (m): 25///characteristics_ch1.6: death (1): 1///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: yoshikou@med.niigata-u.ac.jp///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432240/GSM432240.txt.gz///data_row_count: 41000///relation: "
"GSM432242"	"Serous ovarian cancer 123"	NA	"tumor"	"ser"	"ov"	NA	"low"	"late"	3	"c"	2	NA	"y"	"y"	NA	450	"recurrence"	660	"deceased"	NA	NA	NA	NA	"suboptimal"	NA	NA	NA	NA	"title: Serous ovarian cancer 123///geo_accession: GSM432242///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 2///characteristics_ch1.1: Stage: IIIc///characteristics_ch1.2: cytoreductive surgery: not optimal///characteristics_ch1.3: progression-free survival (m): 15///characteristics_ch1.4: recurrence (1): 1///characteristics_ch1.5: overall survival (m): 22///characteristics_ch1.6: death (1): 1///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: yoshikou@med.niigata-u.ac.jp///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432242/GSM432242.txt.gz///data_row_count: 41000///relation: "
"GSM432243"	"Serous ovarian cancer 127"	NA	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	NA	"y"	"y"	NA	690	"recurrence"	1590	"deceased"	NA	NA	NA	NA	"suboptimal"	NA	NA	NA	NA	"title: Serous ovarian cancer 127///geo_accession: GSM432243///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 3///characteristics_ch1.1: Stage: IIIc///characteristics_ch1.2: cytoreductive surgery: not optimal///characteristics_ch1.3: progression-free survival (m): 23///characteristics_ch1.4: recurrence (1): 1///characteristics_ch1.5: overall survival (m): 53///characteristics_ch1.6: death (1): 1///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: yoshikou@med.niigata-u.ac.jp///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432243/GSM432243.txt.gz///data_row_count: 41000///relation: "
"GSM432244"	"Serous ovarian cancer 129"	NA	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	NA	"y"	"y"	NA	360	"recurrence"	390	"deceased"	NA	NA	NA	NA	"optimal"	NA	NA	NA	NA	"title: Serous ovarian cancer 129///geo_accession: GSM432244///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 3///characteristics_ch1.1: Stage: IIIc///characteristics_ch1.2: cytoreductive surgery: optimal///characteristics_ch1.3: progression-free survival (m): 12///characteristics_ch1.4: recurrence (1): 1///characteristics_ch1.5: overall survival (m): 13///characteristics_ch1.6: death (1): 1///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: yoshikou@med.niigata-u.ac.jp///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432244/GSM432244.txt.gz///data_row_count: 41000///relation: "
"GSM432245"	"Serous ovarian cancer 130"	NA	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	NA	"y"	"y"	NA	750	"recurrence"	2370	"living"	NA	NA	NA	NA	"suboptimal"	NA	NA	NA	NA	"title: Serous ovarian cancer 130///geo_accession: GSM432245///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 3///characteristics_ch1.1: Stage: IIIc///characteristics_ch1.2: cytoreductive surgery: not optimal///characteristics_ch1.3: progression-free survival (m): 25///characteristics_ch1.4: recurrence (1): 1///characteristics_ch1.5: overall survival (m): 79///characteristics_ch1.6: death (1): 0///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: yoshikou@med.niigata-u.ac.jp///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432245/GSM432245.txt.gz///data_row_count: 41000///relation: "
"GSM432246"	"Serous ovarian cancer 131"	NA	"tumor"	"ser"	"ov"	NA	"low"	"late"	3	"a"	1	NA	"y"	"y"	NA	2220	"norecurrence"	2220	"living"	NA	NA	NA	NA	"optimal"	NA	NA	NA	NA	"title: Serous ovarian cancer 131///geo_accession: GSM432246///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 1///characteristics_ch1.1: Stage: IIIa///characteristics_ch1.2: cytoreductive surgery: optimal///characteristics_ch1.3: progression-free survival (m): 74///characteristics_ch1.4: recurrence (1): 0///characteristics_ch1.5: overall survival (m): 74///characteristics_ch1.6: death (1): 0///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: yoshikou@med.niigata-u.ac.jp///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432246/GSM432246.txt.gz///data_row_count: 41000///relation: "
"GSM432247"	"Serous ovarian cancer 132"	NA	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	NA	"y"	"y"	NA	2250	"norecurrence"	2250	"living"	NA	NA	NA	NA	"optimal"	NA	NA	NA	NA	"title: Serous ovarian cancer 132///geo_accession: GSM432247///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 3///characteristics_ch1.1: Stage: IIIc///characteristics_ch1.2: cytoreductive surgery: optimal///characteristics_ch1.3: progression-free survival (m): 75///characteristics_ch1.4: recurrence (1): 0///characteristics_ch1.5: overall survival (m): 75///characteristics_ch1.6: death (1): 0///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: yoshikou@med.niigata-u.ac.jp///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432247/GSM432247.txt.gz///data_row_count: 41000///relation: "
"GSM432248"	"Serous ovarian cancer 134"	NA	"tumor"	"ser"	"ov"	NA	"low"	"late"	3	"a"	2	NA	"y"	"y"	NA	900	"recurrence"	1860	"deceased"	NA	NA	NA	NA	"optimal"	NA	NA	NA	NA	"title: Serous ovarian cancer 134///geo_accession: GSM432248///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 2///characteristics_ch1.1: Stage: IIIa///characteristics_ch1.2: cytoreductive surgery: optimal///characteristics_ch1.3: progression-free survival (m): 30///characteristics_ch1.4: recurrence (1): 1///characteristics_ch1.5: overall survival (m): 62///characteristics_ch1.6: death (1): 1///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: yoshikou@med.niigata-u.ac.jp///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432248/GSM432248.txt.gz///data_row_count: 41000///relation: "
"GSM432249"	"Serous ovarian cancer 136"	NA	"tumor"	"ser"	"ov"	NA	"low"	"late"	3	"c"	2	NA	"y"	"y"	NA	1920	"norecurrence"	1920	"living"	NA	NA	NA	NA	"optimal"	NA	NA	NA	NA	"title: Serous ovarian cancer 136///geo_accession: GSM432249///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 2///characteristics_ch1.1: Stage: IIIc///characteristics_ch1.2: cytoreductive surgery: optimal///characteristics_ch1.3: progression-free survival (m): 64///characteristics_ch1.4: recurrence (1): 0///characteristics_ch1.5: overall survival (m): 64///characteristics_ch1.6: death (1): 0///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: yoshikou@med.niigata-u.ac.jp///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432249/GSM432249.txt.gz///data_row_count: 41000///relation: "
"GSM432250"	"Serous ovarian cancer 137"	NA	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	NA	"y"	"y"	NA	1380	"norecurrence"	1380	"living"	NA	NA	NA	NA	"optimal"	NA	NA	NA	NA	"title: Serous ovarian cancer 137///geo_accession: GSM432250///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 3///characteristics_ch1.1: Stage: IIIc///characteristics_ch1.2: cytoreductive surgery: optimal///characteristics_ch1.3: progression-free survival (m): 46///characteristics_ch1.4: recurrence (1): 0///characteristics_ch1.5: overall survival (m): 46///characteristics_ch1.6: death (1): 0///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: yoshikou@med.niigata-u.ac.jp///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432250/GSM432250.txt.gz///data_row_count: 41000///relation: "
"GSM432251"	"Serous ovarian cancer 139"	NA	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	NA	"y"	"y"	NA	1050	"recurrence"	1320	"living"	NA	NA	NA	NA	"optimal"	NA	NA	NA	NA	"title: Serous ovarian cancer 139///geo_accession: GSM432251///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 3///characteristics_ch1.1: Stage: IIIc///characteristics_ch1.2: cytoreductive surgery: optimal///characteristics_ch1.3: progression-free survival (m): 35///characteristics_ch1.4: recurrence (1): 1///characteristics_ch1.5: overall survival (m): 44///characteristics_ch1.6: death (1): 0///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: yoshikou@med.niigata-u.ac.jp///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432251/GSM432251.txt.gz///data_row_count: 41000///relation: "
"GSM432252"	"Serous ovarian cancer 140"	NA	"tumor"	"ser"	"ov"	NA	"high"	"late"	4	NA	3	NA	"y"	"y"	NA	420	"recurrence"	840	"deceased"	NA	NA	NA	NA	"suboptimal"	NA	NA	NA	NA	"title: Serous ovarian cancer 140///geo_accession: GSM432252///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 3///characteristics_ch1.1: Stage: IV///characteristics_ch1.2: cytoreductive surgery: not optimal///characteristics_ch1.3: progression-free survival (m): 14///characteristics_ch1.4: recurrence (1): 1///characteristics_ch1.5: overall survival (m): 28///characteristics_ch1.6: death (1): 1///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: yoshikou@med.niigata-u.ac.jp///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432252/GSM432252.txt.gz///data_row_count: 41000///relation: "
"GSM432253"	"Serous ovarian cancer 143"	NA	"tumor"	"ser"	"ov"	NA	"low"	"late"	3	"c"	2	NA	"y"	"y"	NA	180	"recurrence"	990	"living"	NA	NA	NA	NA	"suboptimal"	NA	NA	NA	NA	"title: Serous ovarian cancer 143///geo_accession: GSM432253///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 2///characteristics_ch1.1: Stage: IIIc///characteristics_ch1.2: cytoreductive surgery: not optimal///characteristics_ch1.3: progression-free survival (m): 6///characteristics_ch1.4: recurrence (1): 1///characteristics_ch1.5: overall survival (m): 33///characteristics_ch1.6: death (1): 0///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: yoshikou@med.niigata-u.ac.jp///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432253/GSM432253.txt.gz///data_row_count: 41000///relation: "
"GSM432254"	"Serous ovarian cancer 144"	NA	"tumor"	"ser"	"ov"	NA	"high"	"late"	4	NA	3	NA	"y"	"y"	NA	780	"recurrence"	930	"living"	NA	NA	NA	NA	"suboptimal"	NA	NA	NA	NA	"title: Serous ovarian cancer 144///geo_accession: GSM432254///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 3///characteristics_ch1.1: Stage: IV///characteristics_ch1.2: cytoreductive surgery: not optimal///characteristics_ch1.3: progression-free survival (m): 26///characteristics_ch1.4: recurrence (1): 1///characteristics_ch1.5: overall survival (m): 31///characteristics_ch1.6: death (1): 0///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: yoshikou@med.niigata-u.ac.jp///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432254/GSM432254.txt.gz///data_row_count: 41000///relation: "
"GSM432255"	"Serous ovarian cancer 145"	NA	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	NA	"y"	"y"	NA	720	"recurrence"	840	"living"	NA	NA	NA	NA	"suboptimal"	NA	NA	NA	NA	"title: Serous ovarian cancer 145///geo_accession: GSM432255///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 3///characteristics_ch1.1: Stage: IIIc///characteristics_ch1.2: cytoreductive surgery: not optimal///characteristics_ch1.3: progression-free survival (m): 24///characteristics_ch1.4: recurrence (1): 1///characteristics_ch1.5: overall survival (m): 28///characteristics_ch1.6: death (1): 0///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: yoshikou@med.niigata-u.ac.jp///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432255/GSM432255.txt.gz///data_row_count: 41000///relation: "
"GSM432256"	"Serous ovarian cancer 146"	NA	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"b"	3	NA	"y"	"y"	NA	720	"norecurrence"	720	"living"	NA	NA	NA	NA	"suboptimal"	NA	NA	NA	NA	"title: Serous ovarian cancer 146///geo_accession: GSM432256///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 3///characteristics_ch1.1: Stage: IIIb///characteristics_ch1.2: cytoreductive surgery: not optimal///characteristics_ch1.3: progression-free survival (m): 24///characteristics_ch1.4: recurrence (1): 0///characteristics_ch1.5: overall survival (m): 24///characteristics_ch1.6: death (1): 0///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: yoshikou@med.niigata-u.ac.jp///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432256/GSM432256.txt.gz///data_row_count: 41000///relation: "
"GSM432257"	"Serous ovarian cancer 148"	NA	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	NA	"y"	"y"	NA	450	"norecurrence"	450	"living"	NA	NA	NA	NA	"optimal"	NA	NA	NA	NA	"title: Serous ovarian cancer 148///geo_accession: GSM432257///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 3///characteristics_ch1.1: Stage: IIIc///characteristics_ch1.2: cytoreductive surgery: optimal///characteristics_ch1.3: progression-free survival (m): 15///characteristics_ch1.4: recurrence (1): 0///characteristics_ch1.5: overall survival (m): 15///characteristics_ch1.6: death (1): 0///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: yoshikou@med.niigata-u.ac.jp///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432257/GSM432257.txt.gz///data_row_count: 41000///relation: "
"GSM432258"	"Serous ovarian cancer 149"	NA	"tumor"	"ser"	"ov"	NA	"low"	"late"	3	"c"	2	NA	"y"	"y"	NA	450	"norecurrence"	450	"living"	NA	NA	NA	NA	"optimal"	NA	NA	NA	NA	"title: Serous ovarian cancer 149///geo_accession: GSM432258///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 2///characteristics_ch1.1: Stage: IIIc///characteristics_ch1.2: cytoreductive surgery: optimal///characteristics_ch1.3: progression-free survival (m): 15///characteristics_ch1.4: recurrence (1): 0///characteristics_ch1.5: overall survival (m): 15///characteristics_ch1.6: death (1): 0///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: yoshikou@med.niigata-u.ac.jp///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432258/GSM432258.txt.gz///data_row_count: 41000///relation: "
"GSM432259"	"Serous ovarian cancer 15"	NA	"tumor"	"ser"	"ov"	NA	"low"	"late"	3	"b"	2	NA	"y"	"y"	NA	540	"recurrence"	1470	"living"	NA	NA	NA	NA	"optimal"	NA	NA	NA	NA	"title: Serous ovarian cancer 15///geo_accession: GSM432259///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 2///characteristics_ch1.1: Stage: IIIb///characteristics_ch1.2: cytoreductive surgery: optimal///characteristics_ch1.3: progression-free survival (m): 18///characteristics_ch1.4: recurrence (1): 1///characteristics_ch1.5: overall survival (m): 49///characteristics_ch1.6: death (1): 0///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: yoshikou@med.niigata-u.ac.jp///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432259/GSM432259.txt.gz///data_row_count: 41000///relation: "
"GSM432260"	"Serous ovarian cancer 150"	NA	"tumor"	"ser"	"ov"	NA	"low"	"late"	3	"c"	2	NA	"y"	"y"	NA	420	"norecurrence"	420	"living"	NA	NA	NA	NA	"suboptimal"	NA	NA	NA	NA	"title: Serous ovarian cancer 150///geo_accession: GSM432260///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 2///characteristics_ch1.1: Stage: IIIc///characteristics_ch1.2: cytoreductive surgery: not optimal///characteristics_ch1.3: progression-free survival (m): 14///characteristics_ch1.4: recurrence (1): 0///characteristics_ch1.5: overall survival (m): 14///characteristics_ch1.6: death (1): 0///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: yoshikou@med.niigata-u.ac.jp///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432260/GSM432260.txt.gz///data_row_count: 41000///relation: "
"GSM432261"	"Serous ovarian cancer 151"	NA	"tumor"	"ser"	"ov"	NA	"low"	"late"	3	"c"	1	NA	"y"	"y"	NA	390	"norecurrence"	390	"living"	NA	NA	NA	NA	"optimal"	NA	NA	NA	NA	"title: Serous ovarian cancer 151///geo_accession: GSM432261///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 1///characteristics_ch1.1: Stage: IIIc///characteristics_ch1.2: cytoreductive surgery: optimal///characteristics_ch1.3: progression-free survival (m): 13///characteristics_ch1.4: recurrence (1): 0///characteristics_ch1.5: overall survival (m): 13///characteristics_ch1.6: death (1): 0///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: yoshikou@med.niigata-u.ac.jp///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432261/GSM432261.txt.gz///data_row_count: 41000///relation: "
"GSM432262"	"Serous ovarian cancer 154"	NA	"tumor"	"ser"	"ov"	NA	"low"	"late"	3	"b"	2	NA	"y"	"y"	NA	270	"recurrence"	270	"living"	NA	NA	NA	NA	"optimal"	NA	NA	NA	NA	"title: Serous ovarian cancer 154///geo_accession: GSM432262///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 2///characteristics_ch1.1: Stage: IIIb///characteristics_ch1.2: cytoreductive surgery: optimal///characteristics_ch1.3: progression-free survival (m): 9///characteristics_ch1.4: recurrence (1): 1///characteristics_ch1.5: overall survival (m): 9///characteristics_ch1.6: death (1): 0///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: yoshikou@med.niigata-u.ac.jp///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432262/GSM432262.txt.gz///data_row_count: 41000///relation: "
"GSM432263"	"Serous ovarian cancer 156"	NA	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	NA	"y"	"y"	NA	870	"norecurrence"	870	"living"	NA	NA	NA	NA	"optimal"	NA	NA	NA	NA	"title: Serous ovarian cancer 156///geo_accession: GSM432263///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 3///characteristics_ch1.1: Stage: IIIc///characteristics_ch1.2: cytoreductive surgery: optimal///characteristics_ch1.3: progression-free survival (m): 29///characteristics_ch1.4: recurrence (1): 0///characteristics_ch1.5: overall survival (m): 29///characteristics_ch1.6: death (1): 0///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: yoshikou@med.niigata-u.ac.jp///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432263/GSM432263.txt.gz///data_row_count: 41000///relation: "
"GSM432264"	"Serous ovarian cancer 157"	NA	"tumor"	"ser"	"ov"	NA	"low"	"late"	3	"b"	2	NA	"y"	"y"	NA	780	"norecurrence"	780	"living"	NA	NA	NA	NA	"optimal"	NA	NA	NA	NA	"title: Serous ovarian cancer 157///geo_accession: GSM432264///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 2///characteristics_ch1.1: Stage: IIIb///characteristics_ch1.2: cytoreductive surgery: optimal///characteristics_ch1.3: progression-free survival (m): 26///characteristics_ch1.4: recurrence (1): 0///characteristics_ch1.5: overall survival (m): 26///characteristics_ch1.6: death (1): 0///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: yoshikou@med.niigata-u.ac.jp///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432264/GSM432264.txt.gz///data_row_count: 41000///relation: "
"GSM432265"	"Serous ovarian cancer 16"	NA	"tumor"	"ser"	"ov"	NA	"low"	"late"	3	"c"	1	NA	"y"	"y"	NA	390	"recurrence"	1470	"living"	NA	NA	NA	NA	"optimal"	NA	NA	NA	NA	"title: Serous ovarian cancer 16///geo_accession: GSM432265///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 1///characteristics_ch1.1: Stage: IIIc///characteristics_ch1.2: cytoreductive surgery: optimal///characteristics_ch1.3: progression-free survival (m): 13///characteristics_ch1.4: recurrence (1): 1///characteristics_ch1.5: overall survival (m): 49///characteristics_ch1.6: death (1): 0///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: yoshikou@med.niigata-u.ac.jp///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432265/GSM432265.txt.gz///data_row_count: 41000///relation: "
"GSM432266"	"Serous ovarian cancer 160"	NA	"tumor"	"ser"	"ov"	NA	"low"	"late"	3	"c"	2	NA	"y"	"y"	NA	480	"recurrence"	600	"living"	NA	NA	NA	NA	"suboptimal"	NA	NA	NA	NA	"title: Serous ovarian cancer 160///geo_accession: GSM432266///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 2///characteristics_ch1.1: Stage: IIIc///characteristics_ch1.2: cytoreductive surgery: not optimal///characteristics_ch1.3: progression-free survival (m): 16///characteristics_ch1.4: recurrence (1): 1///characteristics_ch1.5: overall survival (m): 20///characteristics_ch1.6: death (1): 0///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: yoshikou@med.niigata-u.ac.jp///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432266/GSM432266.txt.gz///data_row_count: 41000///relation: "
"GSM432267"	"Serous ovarian cancer 17"	NA	"tumor"	"ser"	"ov"	NA	"low"	"late"	3	"b"	2	NA	"y"	"y"	NA	1410	"norecurrence"	1410	"living"	NA	NA	NA	NA	"optimal"	NA	NA	NA	NA	"title: Serous ovarian cancer 17///geo_accession: GSM432267///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 2///characteristics_ch1.1: Stage: IIIb///characteristics_ch1.2: cytoreductive surgery: optimal///characteristics_ch1.3: progression-free survival (m): 47///characteristics_ch1.4: recurrence (1): 0///characteristics_ch1.5: overall survival (m): 47///characteristics_ch1.6: death (1): 0///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: yoshikou@med.niigata-u.ac.jp///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432267/GSM432267.txt.gz///data_row_count: 41000///relation: "
"GSM432268"	"Serous ovarian cancer 171"	NA	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	NA	"y"	"y"	NA	90	"recurrence"	450	"deceased"	NA	NA	NA	NA	"suboptimal"	NA	NA	NA	NA	"title: Serous ovarian cancer 171///geo_accession: GSM432268///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 3///characteristics_ch1.1: Stage: IIIc///characteristics_ch1.2: cytoreductive surgery: not optimal///characteristics_ch1.3: progression-free survival (m): 3///characteristics_ch1.4: recurrence (1): 1///characteristics_ch1.5: overall survival (m): 15///characteristics_ch1.6: death (1): 1///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: yoshikou@med.niigata-u.ac.jp///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432268/GSM432268.txt.gz///data_row_count: 41000///relation: "
"GSM432269"	"Serous ovarian cancer 172"	NA	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	NA	"y"	"y"	NA	60	"recurrence"	360	"deceased"	NA	NA	NA	NA	"suboptimal"	NA	NA	NA	NA	"title: Serous ovarian cancer 172///geo_accession: GSM432269///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 3///characteristics_ch1.1: Stage: IIIc///characteristics_ch1.2: cytoreductive surgery: not optimal///characteristics_ch1.3: progression-free survival (m): 2///characteristics_ch1.4: recurrence (1): 1///characteristics_ch1.5: overall survival (m): 12///characteristics_ch1.6: death (1): 1///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: yoshikou@med.niigata-u.ac.jp///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432269/GSM432269.txt.gz///data_row_count: 41000///relation: "
"GSM432270"	"Serous ovarian cancer 173"	NA	"tumor"	"ser"	"ov"	NA	"low"	"late"	3	"c"	2	NA	"y"	"y"	NA	150	"recurrence"	780	"deceased"	NA	NA	NA	NA	"suboptimal"	NA	NA	NA	NA	"title: Serous ovarian cancer 173///geo_accession: GSM432270///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 2///characteristics_ch1.1: Stage: IIIc///characteristics_ch1.2: cytoreductive surgery: not optimal///characteristics_ch1.3: progression-free survival (m): 5///characteristics_ch1.4: recurrence (1): 1///characteristics_ch1.5: overall survival (m): 26///characteristics_ch1.6: death (1): 1///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: yoshikou@med.niigata-u.ac.jp///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432270/GSM432270.txt.gz///data_row_count: 41000///relation: "
"GSM432271"	"Serous ovarian cancer 174"	NA	"tumor"	"ser"	"ov"	NA	"high"	"late"	4	NA	3	NA	"y"	"y"	NA	690	"recurrence"	1230	"deceased"	NA	NA	NA	NA	"optimal"	NA	NA	NA	NA	"title: Serous ovarian cancer 174///geo_accession: GSM432271///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 3///characteristics_ch1.1: Stage: IV///characteristics_ch1.2: cytoreductive surgery: optimal///characteristics_ch1.3: progression-free survival (m): 23///characteristics_ch1.4: recurrence (1): 1///characteristics_ch1.5: overall survival (m): 41///characteristics_ch1.6: death (1): 1///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: yoshikou@med.niigata-u.ac.jp///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432271/GSM432271.txt.gz///data_row_count: 41000///relation: "
"GSM432272"	"Serous ovarian cancer 176"	NA	"tumor"	"ser"	"ov"	NA	"high"	"late"	4	NA	3	NA	"y"	"y"	NA	30	"recurrence"	330	"deceased"	NA	NA	NA	NA	"suboptimal"	NA	NA	NA	NA	"title: Serous ovarian cancer 176///geo_accession: GSM432272///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 3///characteristics_ch1.1: Stage: IV///characteristics_ch1.2: cytoreductive surgery: not optimal///characteristics_ch1.3: progression-free survival (m): 1///characteristics_ch1.4: recurrence (1): 1///characteristics_ch1.5: overall survival (m): 11///characteristics_ch1.6: death (1): 1///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: yoshikou@med.niigata-u.ac.jp///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432272/GSM432272.txt.gz///data_row_count: 41000///relation: "
"GSM432273"	"Serous ovarian cancer 178"	NA	"tumor"	"ser"	"ov"	NA	"high"	"late"	4	NA	3	NA	"y"	"y"	NA	510	"recurrence"	1410	"deceased"	NA	NA	NA	NA	"optimal"	NA	NA	NA	NA	"title: Serous ovarian cancer 178///geo_accession: GSM432273///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 3///characteristics_ch1.1: Stage: IV///characteristics_ch1.2: cytoreductive surgery: optimal///characteristics_ch1.3: progression-free survival (m): 17///characteristics_ch1.4: recurrence (1): 1///characteristics_ch1.5: overall survival (m): 47///characteristics_ch1.6: death (1): 1///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: yoshikou@med.niigata-u.ac.jp///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432273/GSM432273.txt.gz///data_row_count: 41000///relation: "
"GSM432274"	"Serous ovarian cancer 18"	NA	"tumor"	"ser"	"ov"	NA	"low"	"late"	3	"c"	1	NA	"y"	"y"	NA	1500	"norecurrence"	1500	"living"	NA	NA	NA	NA	"optimal"	NA	NA	NA	NA	"title: Serous ovarian cancer 18///geo_accession: GSM432274///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 1///characteristics_ch1.1: Stage: IIIc///characteristics_ch1.2: cytoreductive surgery: optimal///characteristics_ch1.3: progression-free survival (m): 50///characteristics_ch1.4: recurrence (1): 0///characteristics_ch1.5: overall survival (m): 50///characteristics_ch1.6: death (1): 0///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: yoshikou@med.niigata-u.ac.jp///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432274/GSM432274.txt.gz///data_row_count: 41000///relation: "
"GSM432275"	"Serous ovarian cancer 182"	NA	"tumor"	"ser"	"ov"	NA	"low"	"late"	3	"c"	2	NA	"y"	"y"	NA	30	"recurrence"	30	"deceased"	NA	NA	NA	NA	"suboptimal"	NA	NA	NA	NA	"title: Serous ovarian cancer 182///geo_accession: GSM432275///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 2///characteristics_ch1.1: Stage: IIIc///characteristics_ch1.2: cytoreductive surgery: not optimal///characteristics_ch1.3: progression-free survival (m): 1///characteristics_ch1.4: recurrence (1): 1///characteristics_ch1.5: overall survival (m): 1///characteristics_ch1.6: death (1): 1///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: yoshikou@med.niigata-u.ac.jp///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432275/GSM432275.txt.gz///data_row_count: 41000///relation: "
"GSM432276"	"Serous ovarian cancer 183"	NA	"tumor"	"ser"	"ov"	NA	"low"	"late"	3	"c"	2	NA	"y"	"y"	NA	2160	"norecurrence"	2160	"living"	NA	NA	NA	NA	"suboptimal"	NA	NA	NA	NA	"title: Serous ovarian cancer 183///geo_accession: GSM432276///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 2///characteristics_ch1.1: Stage: IIIc///characteristics_ch1.2: cytoreductive surgery: not optimal///characteristics_ch1.3: progression-free survival (m): 72///characteristics_ch1.4: recurrence (1): 0///characteristics_ch1.5: overall survival (m): 72///characteristics_ch1.6: death (1): 0///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: yoshikou@med.niigata-u.ac.jp///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432276/GSM432276.txt.gz///data_row_count: 41000///relation: "
"GSM432277"	"Serous ovarian cancer 184"	NA	"tumor"	"ser"	"ov"	NA	"low"	"late"	3	"c"	2	NA	"y"	"y"	NA	1950	"norecurrence"	1950	"living"	NA	NA	NA	NA	"optimal"	NA	NA	NA	NA	"title: Serous ovarian cancer 184///geo_accession: GSM432277///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 2///characteristics_ch1.1: Stage: IIIc///characteristics_ch1.2: cytoreductive surgery: optimal///characteristics_ch1.3: progression-free survival (m): 65///characteristics_ch1.4: recurrence (1): 0///characteristics_ch1.5: overall survival (m): 65///characteristics_ch1.6: death (1): 0///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: yoshikou@med.niigata-u.ac.jp///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432277/GSM432277.txt.gz///data_row_count: 41000///relation: "
"GSM432278"	"Serous ovarian cancer 185"	NA	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	NA	"y"	"y"	NA	600	"recurrence"	990	"living"	NA	NA	NA	NA	"optimal"	NA	NA	NA	NA	"title: Serous ovarian cancer 185///geo_accession: GSM432278///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 3///characteristics_ch1.1: Stage: IIIc///characteristics_ch1.2: cytoreductive surgery: optimal///characteristics_ch1.3: progression-free survival (m): 20///characteristics_ch1.4: recurrence (1): 1///characteristics_ch1.5: overall survival (m): 33///characteristics_ch1.6: death (1): 0///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: yoshikou@med.niigata-u.ac.jp///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432278/GSM432278.txt.gz///data_row_count: 41000///relation: "
"GSM432279"	"Serous ovarian cancer 186"	NA	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	NA	"y"	"y"	NA	360	"recurrence"	870	"living"	NA	NA	NA	NA	"optimal"	NA	NA	NA	NA	"title: Serous ovarian cancer 186///geo_accession: GSM432279///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 3///characteristics_ch1.1: Stage: IIIc///characteristics_ch1.2: cytoreductive surgery: optimal///characteristics_ch1.3: progression-free survival (m): 12///characteristics_ch1.4: recurrence (1): 1///characteristics_ch1.5: overall survival (m): 29///characteristics_ch1.6: death (1): 0///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: yoshikou@med.niigata-u.ac.jp///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432279/GSM432279.txt.gz///data_row_count: 41000///relation: "
"GSM432280"	"Serous ovarian cancer 2"	NA	"tumor"	"ser"	"ov"	NA	"low"	"late"	3	"c"	2	NA	"y"	"y"	NA	540	"recurrence"	1470	"deceased"	NA	NA	NA	NA	"suboptimal"	NA	NA	NA	NA	"title: Serous ovarian cancer 2///geo_accession: GSM432280///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 2///characteristics_ch1.1: Stage: IIIc///characteristics_ch1.2: cytoreductive surgery: not optimal///characteristics_ch1.3: progression-free survival (m): 18///characteristics_ch1.4: recurrence (1): 1///characteristics_ch1.5: overall survival (m): 49///characteristics_ch1.6: death (1): 1///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: yoshikou@med.niigata-u.ac.jp///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432280/GSM432280.txt.gz///data_row_count: 41000///relation: "
"GSM432281"	"Serous ovarian cancer 20"	NA	"tumor"	"ser"	"ov"	NA	"low"	"late"	3	"c"	2	NA	"y"	"y"	NA	2100	"norecurrence"	2100	"living"	NA	NA	NA	NA	"optimal"	NA	NA	NA	NA	"title: Serous ovarian cancer 20///geo_accession: GSM432281///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 2///characteristics_ch1.1: Stage: IIIc///characteristics_ch1.2: cytoreductive surgery: optimal///characteristics_ch1.3: progression-free survival (m): 70///characteristics_ch1.4: recurrence (1): 0///characteristics_ch1.5: overall survival (m): 70///characteristics_ch1.6: death (1): 0///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: yoshikou@med.niigata-u.ac.jp///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432281/GSM432281.txt.gz///data_row_count: 41000///relation: "
"GSM432282"	"Serous ovarian cancer 22"	NA	"tumor"	"ser"	"ov"	NA	"low"	"late"	3	"c"	2	NA	"y"	"y"	NA	450	"norecurrence"	450	"living"	NA	NA	NA	NA	"suboptimal"	NA	NA	NA	NA	"title: Serous ovarian cancer 22///geo_accession: GSM432282///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 2///characteristics_ch1.1: Stage: IIIc///characteristics_ch1.2: cytoreductive surgery: not optimal///characteristics_ch1.3: progression-free survival (m): 15///characteristics_ch1.4: recurrence (1): 0///characteristics_ch1.5: overall survival (m): 15///characteristics_ch1.6: death (1): 0///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: yoshikou@med.niigata-u.ac.jp///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432282/GSM432282.txt.gz///data_row_count: 41000///relation: "
"GSM432283"	"Serous ovarian cancer 23"	NA	"tumor"	"ser"	"ov"	NA	"low"	"late"	3	"c"	2	NA	"y"	"y"	NA	60	"recurrence"	240	"deceased"	NA	NA	NA	NA	"suboptimal"	NA	NA	NA	NA	"title: Serous ovarian cancer 23///geo_accession: GSM432283///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 2///characteristics_ch1.1: Stage: IIIc///characteristics_ch1.2: cytoreductive surgery: not optimal///characteristics_ch1.3: progression-free survival (m): 2///characteristics_ch1.4: recurrence (1): 1///characteristics_ch1.5: overall survival (m): 8///characteristics_ch1.6: death (1): 1///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: yoshikou@med.niigata-u.ac.jp///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432283/GSM432283.txt.gz///data_row_count: 41000///relation: "
"GSM432284"	"Serous ovarian cancer 25"	NA	"tumor"	"ser"	"ov"	NA	"low"	"late"	3	"b"	1	NA	"y"	"y"	NA	870	"recurrence"	2400	"deceased"	NA	NA	NA	NA	"optimal"	NA	NA	NA	NA	"title: Serous ovarian cancer 25///geo_accession: GSM432284///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 1///characteristics_ch1.1: Stage: IIIb///characteristics_ch1.2: cytoreductive surgery: optimal///characteristics_ch1.3: progression-free survival (m): 29///characteristics_ch1.4: recurrence (1): 1///characteristics_ch1.5: overall survival (m): 80///characteristics_ch1.6: death (1): 1///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: yoshikou@med.niigata-u.ac.jp///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432284/GSM432284.txt.gz///data_row_count: 41000///relation: "
"GSM432285"	"Serous ovarian cancer 27"	NA	"tumor"	"ser"	"ov"	NA	"low"	"late"	3	"c"	1	NA	"y"	"y"	NA	240	"recurrence"	330	"deceased"	NA	NA	NA	NA	"suboptimal"	NA	NA	NA	NA	"title: Serous ovarian cancer 27///geo_accession: GSM432285///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 1///characteristics_ch1.1: Stage: IIIc///characteristics_ch1.2: cytoreductive surgery: not optimal///characteristics_ch1.3: progression-free survival (m): 8///characteristics_ch1.4: recurrence (1): 1///characteristics_ch1.5: overall survival (m): 11///characteristics_ch1.6: death (1): 1///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: yoshikou@med.niigata-u.ac.jp///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432285/GSM432285.txt.gz///data_row_count: 41000///relation: "
"GSM432286"	"Serous ovarian cancer 31"	NA	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"b"	3	NA	"y"	"y"	NA	60	"recurrence"	150	"deceased"	NA	NA	NA	NA	"optimal"	NA	NA	NA	NA	"title: Serous ovarian cancer 31///geo_accession: GSM432286///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 3///characteristics_ch1.1: Stage: IIIb///characteristics_ch1.2: cytoreductive surgery: optimal///characteristics_ch1.3: progression-free survival (m): 2///characteristics_ch1.4: recurrence (1): 1///characteristics_ch1.5: overall survival (m): 5///characteristics_ch1.6: death (1): 1///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: yoshikou@med.niigata-u.ac.jp///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432286/GSM432286.txt.gz///data_row_count: 41000///relation: "
"GSM432287"	"Serous ovarian cancer 36"	NA	"tumor"	"ser"	"ov"	NA	"low"	"late"	4	NA	1	NA	"y"	"y"	NA	690	"recurrence"	840	"deceased"	NA	NA	NA	NA	"optimal"	NA	NA	NA	NA	"title: Serous ovarian cancer 36///geo_accession: GSM432287///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 1///characteristics_ch1.1: Stage: IV///characteristics_ch1.2: cytoreductive surgery: optimal///characteristics_ch1.3: progression-free survival (m): 23///characteristics_ch1.4: recurrence (1): 1///characteristics_ch1.5: overall survival (m): 28///characteristics_ch1.6: death (1): 1///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: yoshikou@med.niigata-u.ac.jp///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432287/GSM432287.txt.gz///data_row_count: 41000///relation: "
"GSM432288"	"Serous ovarian cancer 37"	NA	"tumor"	"ser"	"ov"	NA	"low"	"late"	3	"c"	2	NA	"y"	"y"	NA	630	"recurrence"	750	"deceased"	NA	NA	NA	NA	"optimal"	NA	NA	NA	NA	"title: Serous ovarian cancer 37///geo_accession: GSM432288///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 2///characteristics_ch1.1: Stage: IIIc///characteristics_ch1.2: cytoreductive surgery: optimal///characteristics_ch1.3: progression-free survival (m): 21///characteristics_ch1.4: recurrence (1): 1///characteristics_ch1.5: overall survival (m): 25///characteristics_ch1.6: death (1): 1///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: yoshikou@med.niigata-u.ac.jp///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432288/GSM432288.txt.gz///data_row_count: 41000///relation: "
"GSM432289"	"Serous ovarian cancer 38"	NA	"tumor"	"ser"	"ov"	NA	"low"	"late"	3	"b"	2	NA	"y"	"y"	NA	450	"recurrence"	1920	"deceased"	NA	NA	NA	NA	"optimal"	NA	NA	NA	NA	"title: Serous ovarian cancer 38///geo_accession: GSM432289///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 2///characteristics_ch1.1: Stage: IIIb///characteristics_ch1.2: cytoreductive surgery: optimal///characteristics_ch1.3: progression-free survival (m): 15///characteristics_ch1.4: recurrence (1): 1///characteristics_ch1.5: overall survival (m): 64///characteristics_ch1.6: death (1): 1///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: yoshikou@med.niigata-u.ac.jp///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432289/GSM432289.txt.gz///data_row_count: 41000///relation: "
"GSM432290"	"Serous ovarian cancer 4"	NA	"tumor"	"ser"	"ov"	NA	"low"	"late"	3	"c"	2	NA	"y"	"y"	NA	60	"recurrence"	1230	"deceased"	NA	NA	NA	NA	"suboptimal"	NA	NA	NA	NA	"title: Serous ovarian cancer 4///geo_accession: GSM432290///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 2///characteristics_ch1.1: Stage: IIIc///characteristics_ch1.2: cytoreductive surgery: not optimal///characteristics_ch1.3: progression-free survival (m): 2///characteristics_ch1.4: recurrence (1): 1///characteristics_ch1.5: overall survival (m): 41///characteristics_ch1.6: death (1): 1///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: yoshikou@med.niigata-u.ac.jp///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432290/GSM432290.txt.gz///data_row_count: 41000///relation: "
"GSM432291"	"Serous ovarian cancer 41"	NA	"tumor"	"ser"	"ov"	NA	"low"	"late"	3	"b"	1	NA	"y"	"y"	NA	1830	"norecurrence"	1830	"living"	NA	NA	NA	NA	"optimal"	NA	NA	NA	NA	"title: Serous ovarian cancer 41///geo_accession: GSM432291///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 1///characteristics_ch1.1: Stage: IIIb///characteristics_ch1.2: cytoreductive surgery: optimal///characteristics_ch1.3: progression-free survival (m): 61///characteristics_ch1.4: recurrence (1): 0///characteristics_ch1.5: overall survival (m): 61///characteristics_ch1.6: death (1): 0///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: yoshikou@med.niigata-u.ac.jp///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432291/GSM432291.txt.gz///data_row_count: 41000///relation: "
"GSM432292"	"Serous ovarian cancer 42"	NA	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	NA	"y"	"y"	NA	510	"recurrence"	1380	"living"	NA	NA	NA	NA	"suboptimal"	NA	NA	NA	NA	"title: Serous ovarian cancer 42///geo_accession: GSM432292///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 3///characteristics_ch1.1: Stage: IIIc///characteristics_ch1.2: cytoreductive surgery: not optimal///characteristics_ch1.3: progression-free survival (m): 17///characteristics_ch1.4: recurrence (1): 1///characteristics_ch1.5: overall survival (m): 46///characteristics_ch1.6: death (1): 0///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: yoshikou@med.niigata-u.ac.jp///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432292/GSM432292.txt.gz///data_row_count: 41000///relation: "
"GSM432293"	"Serous ovarian cancer 43"	NA	"tumor"	"ser"	"ov"	NA	"low"	"late"	3	"c"	2	NA	"y"	"y"	NA	210	"recurrence"	1020	"deceased"	NA	NA	NA	NA	"suboptimal"	NA	NA	NA	NA	"title: Serous ovarian cancer 43///geo_accession: GSM432293///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 2///characteristics_ch1.1: Stage: IIIc///characteristics_ch1.2: cytoreductive surgery: not optimal///characteristics_ch1.3: progression-free survival (m): 7///characteristics_ch1.4: recurrence (1): 1///characteristics_ch1.5: overall survival (m): 34///characteristics_ch1.6: death (1): 1///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: yoshikou@med.niigata-u.ac.jp///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432293/GSM432293.txt.gz///data_row_count: 41000///relation: "
"GSM432294"	"Serous ovarian cancer 44"	NA	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	NA	"y"	"y"	NA	120	"recurrence"	510	"deceased"	NA	NA	NA	NA	"suboptimal"	NA	NA	NA	NA	"title: Serous ovarian cancer 44///geo_accession: GSM432294///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 3///characteristics_ch1.1: Stage: IIIc///characteristics_ch1.2: cytoreductive surgery: not optimal///characteristics_ch1.3: progression-free survival (m): 4///characteristics_ch1.4: recurrence (1): 1///characteristics_ch1.5: overall survival (m): 17///characteristics_ch1.6: death (1): 1///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: yoshikou@med.niigata-u.ac.jp///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432294/GSM432294.txt.gz///data_row_count: 41000///relation: "
"GSM432295"	"Serous ovarian cancer 45"	NA	"tumor"	"ser"	"ov"	NA	"low"	"late"	3	"c"	1	NA	"y"	"y"	NA	1050	"recurrence"	1170	"living"	NA	NA	NA	NA	"optimal"	NA	NA	NA	NA	"title: Serous ovarian cancer 45///geo_accession: GSM432295///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 1///characteristics_ch1.1: Stage: IIIc///characteristics_ch1.2: cytoreductive surgery: optimal///characteristics_ch1.3: progression-free survival (m): 35///characteristics_ch1.4: recurrence (1): 1///characteristics_ch1.5: overall survival (m): 39///characteristics_ch1.6: death (1): 0///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: yoshikou@med.niigata-u.ac.jp///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432295/GSM432295.txt.gz///data_row_count: 41000///relation: "
"GSM432296"	"Serous ovarian cancer 49"	NA	"tumor"	"ser"	"ov"	NA	"low"	"late"	3	"c"	2	NA	"y"	"y"	NA	990	"recurrence"	1110	"living"	NA	NA	NA	NA	"suboptimal"	NA	NA	NA	NA	"title: Serous ovarian cancer 49///geo_accession: GSM432296///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 2///characteristics_ch1.1: Stage: IIIc///characteristics_ch1.2: cytoreductive surgery: not optimal///characteristics_ch1.3: progression-free survival (m): 33///characteristics_ch1.4: recurrence (1): 1///characteristics_ch1.5: overall survival (m): 37///characteristics_ch1.6: death (1): 0///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: yoshikou@med.niigata-u.ac.jp///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432296/GSM432296.txt.gz///data_row_count: 41000///relation: "
"GSM432297"	"Serous ovarian cancer 50"	NA	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	NA	"y"	"y"	NA	240	"recurrence"	990	"deceased"	NA	NA	NA	NA	"optimal"	NA	NA	NA	NA	"title: Serous ovarian cancer 50///geo_accession: GSM432297///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 3///characteristics_ch1.1: Stage: IIIc///characteristics_ch1.2: cytoreductive surgery: optimal///characteristics_ch1.3: progression-free survival (m): 8///characteristics_ch1.4: recurrence (1): 1///characteristics_ch1.5: overall survival (m): 33///characteristics_ch1.6: death (1): 1///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: yoshikou@med.niigata-u.ac.jp///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432297/GSM432297.txt.gz///data_row_count: 41000///relation: "
"GSM432298"	"Serous ovarian cancer 51"	NA	"tumor"	"ser"	"ov"	NA	"low"	"late"	3	"c"	2	NA	"y"	"y"	NA	420	"recurrence"	750	"living"	NA	NA	NA	NA	"suboptimal"	NA	NA	NA	NA	"title: Serous ovarian cancer 51///geo_accession: GSM432298///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 2///characteristics_ch1.1: Stage: IIIc///characteristics_ch1.2: cytoreductive surgery: not optimal///characteristics_ch1.3: progression-free survival (m): 14///characteristics_ch1.4: recurrence (1): 1///characteristics_ch1.5: overall survival (m): 25///characteristics_ch1.6: death (1): 0///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: yoshikou@med.niigata-u.ac.jp///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432298/GSM432298.txt.gz///data_row_count: 41000///relation: "
"GSM432299"	"Serous ovarian cancer 52"	NA	"tumor"	"ser"	"ov"	NA	"high"	"late"	4	NA	3	NA	"y"	"y"	NA	120	"recurrence"	720	"living"	NA	NA	NA	NA	"suboptimal"	NA	NA	NA	NA	"title: Serous ovarian cancer 52///geo_accession: GSM432299///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 3///characteristics_ch1.1: Stage: IV///characteristics_ch1.2: cytoreductive surgery: not optimal///characteristics_ch1.3: progression-free survival (m): 4///characteristics_ch1.4: recurrence (1): 1///characteristics_ch1.5: overall survival (m): 24///characteristics_ch1.6: death (1): 0///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: yoshikou@med.niigata-u.ac.jp///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432299/GSM432299.txt.gz///data_row_count: 41000///relation: "
"GSM432300"	"Serous ovarian cancer 53"	NA	"tumor"	"ser"	"ov"	NA	"high"	"late"	4	NA	3	NA	"y"	"y"	NA	270	"recurrence"	690	"deceased"	NA	NA	NA	NA	"suboptimal"	NA	NA	NA	NA	"title: Serous ovarian cancer 53///geo_accession: GSM432300///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 3///characteristics_ch1.1: Stage: IV///characteristics_ch1.2: cytoreductive surgery: not optimal///characteristics_ch1.3: progression-free survival (m): 9///characteristics_ch1.4: recurrence (1): 1///characteristics_ch1.5: overall survival (m): 23///characteristics_ch1.6: death (1): 1///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: yoshikou@med.niigata-u.ac.jp///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432300/GSM432300.txt.gz///data_row_count: 41000///relation: "
"GSM432301"	"Serous ovarian cancer 54"	NA	"tumor"	"ser"	"ov"	NA	"low"	"late"	3	"b"	1	NA	"y"	"y"	NA	900	"norecurrence"	900	"living"	NA	NA	NA	NA	"optimal"	NA	NA	NA	NA	"title: Serous ovarian cancer 54///geo_accession: GSM432301///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 1///characteristics_ch1.1: Stage: IIIb///characteristics_ch1.2: cytoreductive surgery: optimal///characteristics_ch1.3: progression-free survival (m): 30///characteristics_ch1.4: recurrence (1): 0///characteristics_ch1.5: overall survival (m): 30///characteristics_ch1.6: death (1): 0///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: yoshikou@med.niigata-u.ac.jp///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432301/GSM432301.txt.gz///data_row_count: 41000///relation: "
"GSM432302"	"Serous ovarian cancer 55"	NA	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	NA	"y"	"y"	NA	900	"norecurrence"	900	"living"	NA	NA	NA	NA	"optimal"	NA	NA	NA	NA	"title: Serous ovarian cancer 55///geo_accession: GSM432302///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 3///characteristics_ch1.1: Stage: IIIc///characteristics_ch1.2: cytoreductive surgery: optimal///characteristics_ch1.3: progression-free survival (m): 30///characteristics_ch1.4: recurrence (1): 0///characteristics_ch1.5: overall survival (m): 30///characteristics_ch1.6: death (1): 0///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: yoshikou@med.niigata-u.ac.jp///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432302/GSM432302.txt.gz///data_row_count: 41000///relation: "
"GSM432303"	"Serous ovarian cancer 56"	NA	"tumor"	"ser"	"ov"	NA	"low"	"late"	3	"c"	1	NA	"y"	"y"	NA	420	"recurrence"	870	"living"	NA	NA	NA	NA	"suboptimal"	NA	NA	NA	NA	"title: Serous ovarian cancer 56///geo_accession: GSM432303///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 1///characteristics_ch1.1: Stage: IIIc///characteristics_ch1.2: cytoreductive surgery: not optimal///characteristics_ch1.3: progression-free survival (m): 14///characteristics_ch1.4: recurrence (1): 1///characteristics_ch1.5: overall survival (m): 29///characteristics_ch1.6: death (1): 0///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: yoshikou@med.niigata-u.ac.jp///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432303/GSM432303.txt.gz///data_row_count: 41000///relation: "
"GSM432304"	"Serous ovarian cancer 57"	NA	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	NA	"y"	"y"	NA	360	"recurrence"	690	"living"	NA	NA	NA	NA	"optimal"	NA	NA	NA	NA	"title: Serous ovarian cancer 57///geo_accession: GSM432304///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 3///characteristics_ch1.1: Stage: IIIc///characteristics_ch1.2: cytoreductive surgery: optimal///characteristics_ch1.3: progression-free survival (m): 12///characteristics_ch1.4: recurrence (1): 1///characteristics_ch1.5: overall survival (m): 23///characteristics_ch1.6: death (1): 0///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: yoshikou@med.niigata-u.ac.jp///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432304/GSM432304.txt.gz///data_row_count: 41000///relation: "
"GSM432305"	"Serous ovarian cancer 58"	NA	"tumor"	"ser"	"ov"	NA	"low"	"late"	3	"c"	1	NA	"y"	"y"	NA	390	"recurrence"	600	"living"	NA	NA	NA	NA	"optimal"	NA	NA	NA	NA	"title: Serous ovarian cancer 58///geo_accession: GSM432305///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 1///characteristics_ch1.1: Stage: IIIc///characteristics_ch1.2: cytoreductive surgery: optimal///characteristics_ch1.3: progression-free survival (m): 13///characteristics_ch1.4: recurrence (1): 1///characteristics_ch1.5: overall survival (m): 20///characteristics_ch1.6: death (1): 0///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: yoshikou@med.niigata-u.ac.jp///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432305/GSM432305.txt.gz///data_row_count: 41000///relation: "
"GSM432306"	"Serous ovarian cancer 6"	NA	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	NA	"y"	"y"	NA	360	"recurrence"	960	"deceased"	NA	NA	NA	NA	"optimal"	NA	NA	NA	NA	"title: Serous ovarian cancer 6///geo_accession: GSM432306///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 3///characteristics_ch1.1: Stage: IIIc///characteristics_ch1.2: cytoreductive surgery: optimal///characteristics_ch1.3: progression-free survival (m): 12///characteristics_ch1.4: recurrence (1): 1///characteristics_ch1.5: overall survival (m): 32///characteristics_ch1.6: death (1): 1///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: yoshikou@med.niigata-u.ac.jp///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432306/GSM432306.txt.gz///data_row_count: 41000///relation: "
"GSM432307"	"Serous ovarian cancer 60"	NA	"tumor"	"ser"	"ov"	NA	"low"	"late"	4	NA	2	NA	"y"	"y"	NA	1410	"recurrence"	2430	"living"	NA	NA	NA	NA	"suboptimal"	NA	NA	NA	NA	"title: Serous ovarian cancer 60///geo_accession: GSM432307///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 2///characteristics_ch1.1: Stage: IV///characteristics_ch1.2: cytoreductive surgery: not optimal///characteristics_ch1.3: progression-free survival (m): 47///characteristics_ch1.4: recurrence (1): 1///characteristics_ch1.5: overall survival (m): 81///characteristics_ch1.6: death (1): 0///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: yoshikou@med.niigata-u.ac.jp///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432307/GSM432307.txt.gz///data_row_count: 41000///relation: "
"GSM432308"	"Serous ovarian cancer 61"	NA	"tumor"	"ser"	"ov"	NA	"low"	"late"	3	"c"	1	NA	"y"	"y"	NA	780	"recurrence"	2220	"living"	NA	NA	NA	NA	"suboptimal"	NA	NA	NA	NA	"title: Serous ovarian cancer 61///geo_accession: GSM432308///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 1///characteristics_ch1.1: Stage: IIIc///characteristics_ch1.2: cytoreductive surgery: not optimal///characteristics_ch1.3: progression-free survival (m): 26///characteristics_ch1.4: recurrence (1): 1///characteristics_ch1.5: overall survival (m): 74///characteristics_ch1.6: death (1): 0///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: yoshikou@med.niigata-u.ac.jp///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432308/GSM432308.txt.gz///data_row_count: 41000///relation: "
"GSM432309"	"Serous ovarian cancer 62"	NA	"tumor"	"ser"	"ov"	NA	"low"	"late"	3	"c"	2	NA	"y"	"y"	NA	330	"recurrence"	780	"deceased"	NA	NA	NA	NA	"suboptimal"	NA	NA	NA	NA	"title: Serous ovarian cancer 62///geo_accession: GSM432309///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 2///characteristics_ch1.1: Stage: IIIc///characteristics_ch1.2: cytoreductive surgery: not optimal///characteristics_ch1.3: progression-free survival (m): 11///characteristics_ch1.4: recurrence (1): 1///characteristics_ch1.5: overall survival (m): 26///characteristics_ch1.6: death (1): 1///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: yoshikou@med.niigata-u.ac.jp///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432309/GSM432309.txt.gz///data_row_count: 41000///relation: "
"GSM432310"	"Serous ovarian cancer 64"	NA	"tumor"	"ser"	"ov"	NA	"low"	"late"	3	"c"	2	NA	"y"	"y"	NA	780	"norecurrence"	780	"living"	NA	NA	NA	NA	"optimal"	NA	NA	NA	NA	"title: Serous ovarian cancer 64///geo_accession: GSM432310///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 2///characteristics_ch1.1: Stage: IIIc///characteristics_ch1.2: cytoreductive surgery: optimal///characteristics_ch1.3: progression-free survival (m): 26///characteristics_ch1.4: recurrence (1): 0///characteristics_ch1.5: overall survival (m): 26///characteristics_ch1.6: death (1): 0///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: yoshikou@med.niigata-u.ac.jp///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432310/GSM432310.txt.gz///data_row_count: 41000///relation: "
"GSM432311"	"Serous ovarian cancer 66"	NA	"tumor"	"ser"	"ov"	NA	"low"	"late"	3	"c"	1	NA	"y"	"y"	NA	570	"norecurrence"	570	"living"	NA	NA	NA	NA	"optimal"	NA	NA	NA	NA	"title: Serous ovarian cancer 66///geo_accession: GSM432311///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 1///characteristics_ch1.1: Stage: IIIc///characteristics_ch1.2: cytoreductive surgery: optimal///characteristics_ch1.3: progression-free survival (m): 19///characteristics_ch1.4: recurrence (1): 0///characteristics_ch1.5: overall survival (m): 19///characteristics_ch1.6: death (1): 0///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: yoshikou@med.niigata-u.ac.jp///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432311/GSM432311.txt.gz///data_row_count: 41000///relation: "
"GSM432312"	"Serous ovarian cancer 67"	NA	"tumor"	"ser"	"ov"	NA	"low"	"late"	3	"b"	1	NA	"y"	"y"	NA	660	"norecurrence"	660	"living"	NA	NA	NA	NA	"optimal"	NA	NA	NA	NA	"title: Serous ovarian cancer 67///geo_accession: GSM432312///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 1///characteristics_ch1.1: Stage: IIIb///characteristics_ch1.2: cytoreductive surgery: optimal///characteristics_ch1.3: progression-free survival (m): 22///characteristics_ch1.4: recurrence (1): 0///characteristics_ch1.5: overall survival (m): 22///characteristics_ch1.6: death (1): 0///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: yoshikou@med.niigata-u.ac.jp///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432312/GSM432312.txt.gz///data_row_count: 41000///relation: "
"GSM432313"	"Serous ovarian cancer 68"	NA	"tumor"	"ser"	"ov"	NA	"low"	"late"	3	"a"	1	NA	"y"	"y"	NA	660	"norecurrence"	660	"living"	NA	NA	NA	NA	"optimal"	NA	NA	NA	NA	"title: Serous ovarian cancer 68///geo_accession: GSM432313///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 1///characteristics_ch1.1: Stage: IIIa///characteristics_ch1.2: cytoreductive surgery: optimal///characteristics_ch1.3: progression-free survival (m): 22///characteristics_ch1.4: recurrence (1): 0///characteristics_ch1.5: overall survival (m): 22///characteristics_ch1.6: death (1): 0///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: yoshikou@med.niigata-u.ac.jp///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432313/GSM432313.txt.gz///data_row_count: 41000///relation: "
"GSM432314"	"Serous ovarian cancer 69"	NA	"tumor"	"ser"	"ov"	NA	"low"	"late"	3	"b"	1	NA	"y"	"y"	NA	630	"norecurrence"	630	"living"	NA	NA	NA	NA	"optimal"	NA	NA	NA	NA	"title: Serous ovarian cancer 69///geo_accession: GSM432314///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 1///characteristics_ch1.1: Stage: IIIb///characteristics_ch1.2: cytoreductive surgery: optimal///characteristics_ch1.3: progression-free survival (m): 21///characteristics_ch1.4: recurrence (1): 0///characteristics_ch1.5: overall survival (m): 21///characteristics_ch1.6: death (1): 0///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: yoshikou@med.niigata-u.ac.jp///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432314/GSM432314.txt.gz///data_row_count: 41000///relation: "
"GSM432315"	"Serous ovarian cancer 7"	NA	"tumor"	"ser"	"ov"	NA	"low"	"late"	3	"a"	1	NA	"y"	"y"	NA	570	"recurrence"	1260	"deceased"	NA	NA	NA	NA	"optimal"	NA	NA	NA	NA	"title: Serous ovarian cancer 7///geo_accession: GSM432315///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 1///characteristics_ch1.1: Stage: IIIa///characteristics_ch1.2: cytoreductive surgery: optimal///characteristics_ch1.3: progression-free survival (m): 19///characteristics_ch1.4: recurrence (1): 1///characteristics_ch1.5: overall survival (m): 42///characteristics_ch1.6: death (1): 1///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: yoshikou@med.niigata-u.ac.jp///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432315/GSM432315.txt.gz///data_row_count: 41000///relation: "
"GSM432316"	"Serous ovarian cancer 72"	NA	"tumor"	"ser"	"ov"	NA	"low"	"late"	3	"b"	2	NA	"y"	"y"	NA	390	"recurrence"	780	"deceased"	NA	NA	NA	NA	"optimal"	NA	NA	NA	NA	"title: Serous ovarian cancer 72///geo_accession: GSM432316///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 2///characteristics_ch1.1: Stage: IIIb///characteristics_ch1.2: cytoreductive surgery: optimal///characteristics_ch1.3: progression-free survival (m): 13///characteristics_ch1.4: recurrence (1): 1///characteristics_ch1.5: overall survival (m): 26///characteristics_ch1.6: death (1): 1///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: yoshikou@med.niigata-u.ac.jp///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432316/GSM432316.txt.gz///data_row_count: 41000///relation: "
"GSM432317"	"Serous ovarian cancer 77"	NA	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	NA	"y"	"y"	NA	30	"recurrence"	30	"deceased"	NA	NA	NA	NA	"suboptimal"	NA	NA	NA	NA	"title: Serous ovarian cancer 77///geo_accession: GSM432317///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 3///characteristics_ch1.1: Stage: IIIc///characteristics_ch1.2: cytoreductive surgery: not optimal///characteristics_ch1.3: progression-free survival (m): 1///characteristics_ch1.4: recurrence (1): 1///characteristics_ch1.5: overall survival (m): 1///characteristics_ch1.6: death (1): 1///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: yoshikou@med.niigata-u.ac.jp///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432317/GSM432317.txt.gz///data_row_count: 41000///relation: "
"GSM432318"	"Serous ovarian cancer 79"	NA	"tumor"	"ser"	"ov"	NA	"low"	"late"	3	"c"	1	NA	"y"	"y"	NA	480	"recurrence"	810	"deceased"	NA	NA	NA	NA	"optimal"	NA	NA	NA	NA	"title: Serous ovarian cancer 79///geo_accession: GSM432318///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 1///characteristics_ch1.1: Stage: IIIc///characteristics_ch1.2: cytoreductive surgery: optimal///characteristics_ch1.3: progression-free survival (m): 16///characteristics_ch1.4: recurrence (1): 1///characteristics_ch1.5: overall survival (m): 27///characteristics_ch1.6: death (1): 1///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: yoshikou@med.niigata-u.ac.jp///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432318/GSM432318.txt.gz///data_row_count: 41000///relation: "
"GSM432319"	"Serous ovarian cancer 80"	NA	"tumor"	"ser"	"ov"	NA	"low"	"late"	3	"c"	2	NA	"y"	"y"	NA	360	"recurrence"	2040	"deceased"	NA	NA	NA	NA	"suboptimal"	NA	NA	NA	NA	"title: Serous ovarian cancer 80///geo_accession: GSM432319///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 2///characteristics_ch1.1: Stage: IIIc///characteristics_ch1.2: cytoreductive surgery: not optimal///characteristics_ch1.3: progression-free survival (m): 12///characteristics_ch1.4: recurrence (1): 1///characteristics_ch1.5: overall survival (m): 68///characteristics_ch1.6: death (1): 1///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: yoshikou@med.niigata-u.ac.jp///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432319/GSM432319.txt.gz///data_row_count: 41000///relation: "
"GSM432320"	"Serous ovarian cancer 83"	NA	"tumor"	"ser"	"ov"	NA	"low"	"late"	4	NA	2	NA	"y"	"y"	NA	840	"recurrence"	1920	"living"	NA	NA	NA	NA	"suboptimal"	NA	NA	NA	NA	"title: Serous ovarian cancer 83///geo_accession: GSM432320///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 2///characteristics_ch1.1: Stage: IV///characteristics_ch1.2: cytoreductive surgery: not optimal///characteristics_ch1.3: progression-free survival (m): 28///characteristics_ch1.4: recurrence (1): 1///characteristics_ch1.5: overall survival (m): 64///characteristics_ch1.6: death (1): 0///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: yoshikou@med.niigata-u.ac.jp///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432320/GSM432320.txt.gz///data_row_count: 41000///relation: "
"GSM432321"	"Serous ovarian cancer 85"	NA	"tumor"	"ser"	"ov"	NA	"low"	"late"	3	"a"	1	NA	"y"	"y"	NA	1560	"norecurrence"	1560	"living"	NA	NA	NA	NA	"optimal"	NA	NA	NA	NA	"title: Serous ovarian cancer 85///geo_accession: GSM432321///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 1///characteristics_ch1.1: Stage: IIIa///characteristics_ch1.2: cytoreductive surgery: optimal///characteristics_ch1.3: progression-free survival (m): 52///characteristics_ch1.4: recurrence (1): 0///characteristics_ch1.5: overall survival (m): 52///characteristics_ch1.6: death (1): 0///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: yoshikou@med.niigata-u.ac.jp///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432321/GSM432321.txt.gz///data_row_count: 41000///relation: "
"GSM432322"	"Serous ovarian cancer 88"	NA	"tumor"	"ser"	"ov"	NA	"low"	"late"	4	NA	1	NA	"y"	"y"	NA	1530	"recurrence"	1950	"living"	NA	NA	NA	NA	"optimal"	NA	NA	NA	NA	"title: Serous ovarian cancer 88///geo_accession: GSM432322///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 1///characteristics_ch1.1: Stage: IV///characteristics_ch1.2: cytoreductive surgery: optimal///characteristics_ch1.3: progression-free survival (m): 51///characteristics_ch1.4: recurrence (1): 1///characteristics_ch1.5: overall survival (m): 65///characteristics_ch1.6: death (1): 0///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: yoshikou@med.niigata-u.ac.jp///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432322/GSM432322.txt.gz///data_row_count: 41000///relation: "
"GSM432323"	"Serous ovarian cancer 89"	NA	"tumor"	"ser"	"ov"	NA	"high"	"late"	4	NA	3	NA	"y"	"y"	NA	390	"recurrence"	990	"deceased"	NA	NA	NA	NA	"suboptimal"	NA	NA	NA	NA	"title: Serous ovarian cancer 89///geo_accession: GSM432323///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 3///characteristics_ch1.1: Stage: IV///characteristics_ch1.2: cytoreductive surgery: not optimal///characteristics_ch1.3: progression-free survival (m): 13///characteristics_ch1.4: recurrence (1): 1///characteristics_ch1.5: overall survival (m): 33///characteristics_ch1.6: death (1): 1///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: yoshikou@med.niigata-u.ac.jp///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432323/GSM432323.txt.gz///data_row_count: 41000///relation: "
"GSM432324"	"Serous ovarian cancer 90"	NA	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	"c"	3	NA	"y"	"y"	NA	870	"recurrence"	1530	"deceased"	NA	NA	NA	NA	"suboptimal"	NA	NA	NA	NA	"title: Serous ovarian cancer 90///geo_accession: GSM432324///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 3///characteristics_ch1.1: Stage: IIIc///characteristics_ch1.2: cytoreductive surgery: not optimal///characteristics_ch1.3: progression-free survival (m): 29///characteristics_ch1.4: recurrence (1): 1///characteristics_ch1.5: overall survival (m): 51///characteristics_ch1.6: death (1): 1///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: yoshikou@med.niigata-u.ac.jp///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432324/GSM432324.txt.gz///data_row_count: 41000///relation: "
"GSM432325"	"Serous ovarian cancer 91"	NA	"tumor"	"ser"	"ov"	NA	"low"	"late"	3	"b"	2	NA	"y"	"y"	NA	30	"recurrence"	30	"deceased"	NA	NA	NA	NA	"optimal"	NA	NA	NA	NA	"title: Serous ovarian cancer 91///geo_accession: GSM432325///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 2///characteristics_ch1.1: Stage: IIIb///characteristics_ch1.2: cytoreductive surgery: optimal///characteristics_ch1.3: progression-free survival (m): 1///characteristics_ch1.4: recurrence (1): 1///characteristics_ch1.5: overall survival (m): 1///characteristics_ch1.6: death (1): 1///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: yoshikou@med.niigata-u.ac.jp///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432325/GSM432325.txt.gz///data_row_count: 41000///relation: "
"GSM432326"	"Serous ovarian cancer 92"	NA	"tumor"	"ser"	"ov"	NA	"high"	"late"	4	NA	3	NA	"y"	"y"	NA	90	"recurrence"	1620	"deceased"	NA	NA	NA	NA	"suboptimal"	NA	NA	NA	NA	"title: Serous ovarian cancer 92///geo_accession: GSM432326///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 3///characteristics_ch1.1: Stage: IV///characteristics_ch1.2: cytoreductive surgery: not optimal///characteristics_ch1.3: progression-free survival (m): 3///characteristics_ch1.4: recurrence (1): 1///characteristics_ch1.5: overall survival (m): 54///characteristics_ch1.6: death (1): 1///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: yoshikou@med.niigata-u.ac.jp///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432326/GSM432326.txt.gz///data_row_count: 41000///relation: "
"GSM432327"	"Serous ovarian cancer 93"	NA	"tumor"	"ser"	"ov"	NA	"low"	"late"	3	"b"	2	NA	"y"	"y"	NA	1530	"norecurrence"	1530	"living"	NA	NA	NA	NA	"optimal"	NA	NA	NA	NA	"title: Serous ovarian cancer 93///geo_accession: GSM432327///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 2///characteristics_ch1.1: Stage: IIIb///characteristics_ch1.2: cytoreductive surgery: optimal///characteristics_ch1.3: progression-free survival (m): 51///characteristics_ch1.4: recurrence (1): 0///characteristics_ch1.5: overall survival (m): 51///characteristics_ch1.6: death (1): 0///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: yoshikou@med.niigata-u.ac.jp///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432327/GSM432327.txt.gz///data_row_count: 41000///relation: "
"GSM432328"	"Serous ovarian cancer 94"	NA	"tumor"	"ser"	"ov"	NA	"low"	"late"	4	NA	1	NA	"y"	"y"	NA	600	"recurrence"	1530	"living"	NA	NA	NA	NA	"optimal"	NA	NA	NA	NA	"title: Serous ovarian cancer 94///geo_accession: GSM432328///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 1///characteristics_ch1.1: Stage: IV///characteristics_ch1.2: cytoreductive surgery: optimal///characteristics_ch1.3: progression-free survival (m): 20///characteristics_ch1.4: recurrence (1): 1///characteristics_ch1.5: overall survival (m): 51///characteristics_ch1.6: death (1): 0///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: yoshikou@med.niigata-u.ac.jp///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432328/GSM432328.txt.gz///data_row_count: 41000///relation: "
"GSM432329"	"Serous ovarian cancer 95"	NA	"tumor"	"ser"	"ov"	NA	"low"	"late"	3	"c"	2	NA	"y"	"y"	NA	120	"recurrence"	1170	"living"	NA	NA	NA	NA	"optimal"	NA	NA	NA	NA	"title: Serous ovarian cancer 95///geo_accession: GSM432329///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 2///characteristics_ch1.1: Stage: IIIc///characteristics_ch1.2: cytoreductive surgery: optimal///characteristics_ch1.3: progression-free survival (m): 4///characteristics_ch1.4: recurrence (1): 1///characteristics_ch1.5: overall survival (m): 39///characteristics_ch1.6: death (1): 0///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: yoshikou@med.niigata-u.ac.jp///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432329/GSM432329.txt.gz///data_row_count: 41000///relation: "
"GSM432330"	"Serous ovarian cancer 97"	NA	"tumor"	"ser"	"ov"	NA	"high"	"late"	4	NA	3	NA	"y"	"y"	NA	240	"recurrence"	840	"living"	NA	NA	NA	NA	"suboptimal"	NA	NA	NA	NA	"title: Serous ovarian cancer 97///geo_accession: GSM432330///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 3///characteristics_ch1.1: Stage: IV///characteristics_ch1.2: cytoreductive surgery: not optimal///characteristics_ch1.3: progression-free survival (m): 8///characteristics_ch1.4: recurrence (1): 1///characteristics_ch1.5: overall survival (m): 28///characteristics_ch1.6: death (1): 0///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: yoshikou@med.niigata-u.ac.jp///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432330/GSM432330.txt.gz///data_row_count: 41000///relation: "
